EBV reactivation serological profile in primary Sjögren’s syndrome: an underlying trigger of active articular involvement?

摘要: Antibody to Epstein–Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations clinical/therapeutic features in primary Sjogren’s syndrome (pSS) were not established. We evaluated 100 pSS patients (American–European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Syndrome Activity Index (ESSDAI). Antibodies EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) determined ELISA. Patients controls had comparable frequencies mean levels of anti-VCA IgG (90 vs. 86.5 %, p = 0.501; 2.6 ± 1.1 2.5 AU/mL, 0.737) (92 94.4 0.576; 141.3 69.8 135.6 67.5 RU/mL, 0.464). Anti-VCA IgM negative all cases. Noteworthy, higher frequency increased observed than (36 4.5 < 0.0001; 38.6 57.4 7.9 26.3 0.0001). Further analysis (n 36) without 64) revealed age/gender/ethnicity (p ≥ 0.551), current prednisone dose (4.8 6.9 5.1 10.4 mg/day, 0.319), uses (52.8 37.5 0.148) immunosuppressants (44.4 31.3 0.201). ESSDAI values 0.102), but joint more frequent (25 9.4 0.045) positive patients. Anti-EA-D antibodies anti-Ro/SSA 1.000), anti-La/SSB 0.652), rheumatoid factor anti-α-fodrin 0.390) or antiphospholipid 0.573), suggesting cross-reactivity. The raises the possibility that a subclinical reactivation may trigger perpetuate articular involvement pSS.